Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-09-24 16:30:50 ET · period of report 2026-09-22 · accession 0001610717-26-000422 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-24 16:30 | 2026-09-22 | TXG | SULIMAN SHEHNAAZ | Dir | S - Sale | $81.19 | -5,723 | 23.8K | -19% | -$464.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-09-22 | S | D | 292 | $78.20 | 29,223 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. (F2) This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2026-09-22 | S | D | 614 | $79.51 | 28,609 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2026-09-22 | S | D | 1,325 | $80.82 | 27,284 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Common | Class A Common Stock | 2026-09-22 | S | D | 2,270 | $81.67 | 25,014 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. (F5) This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 5 | Common | Class A Common Stock | 2026-09-22 | S | D | 1,222 | $82.28 | 23,792 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. (F6) This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |